Educational analysis only — not financial advice. Always do your own due diligence.
BMY trades against a final fair-value range of $68.85-$100.89, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
Bristol-Myers Squibb is facing a massive loss of exclusivity wave. A failure in executing its new product launches would transform its 9.1x distressed multiple into a value trap, threatening the sustainability of its 70% dividend payout.
New assets like Opdualag and Camzyos completely fail to offset the multi-billion-dollar revenue crater from the Revlimid and Eliquis patent cliff.
Regulatory and pricing pressures under the Inflation Reduction Act permanently compress operating margins well below the projected 29%.
Management pursues aggressively overpriced acquisitions to patch the pipeline gap, significantly destroying ROIC and elevating debt.
Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net income, accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
